October 24, 2016 1:29 PM ET


Company Overview of Medicago Inc.

Company Overview

Medicago Inc., a clinical-stage biotechnology company, develops novel vaccines and therapeutic proteins to treat various infectious diseases worldwide. The company develops its vaccines based on its proprietary technologies comprising the plant-based Proficia technology and Virus-Like Particles (VLP) technology. Its product candidates include H5N1 pandemic influenza VLP vaccine, which has completed a Phase II human clinical trial; and seasonal influenza and H1N1 vaccines. The company’s products under development also comprise non-influenza VLP and rabies vaccine candidates. It has a strategic alliance with Mitsubishi Tanabe Pharma Corporation to develop a Rotavirus vaccine candidate; and res...

1020 Route de l'Église

Suite 600

Quebec, QC G1V 3V9


Founded in 1997





Key Executives for Medicago Inc.

Chief Executive Officer, President and Director
Executive Vice President of Operations
Director of Investor Relations & Communications
Vice-President of Quality Assurance and Quality Control
Vice President of Manufacturing
Compensation as of Fiscal Year 2016.

Medicago Inc. Key Developments

Medicago Inc. Presents at Bloom Burton & Co Healthcare Investor Conference 2016, May-03-2016 02:00 PM

Medicago Inc. Presents at Bloom Burton & Co Healthcare Investor Conference 2016, May-03-2016 02:00 PM. Venue: Sheraton Centre Toronto Hotel, Toronto, Ontario, Canada.

Canadian Government Engages Medicago to Develop Ebola Monoclonal Antibodies

Medicago has been awarded a contract by the Public Health Agency of Canada (PHAC) to develop two antibodies to fight the Sudan strain of the Ebola virus. Medicago will produce these antibodies at its facility in Quebec City. In producing this technology, Medicago will demonstrate a Canadian capability to manufacture monoclonal antibodies as part of emergency preparedness and response efforts. The Canadian government and Medicago are now working together on antibodies for the Sudan strain lineage, building on existing work directed at the Zaire strain which is responsible for the ongoing outbreak in West Africa.

Medicago to Build $245 Million Production Facility in Quebec City

Medicago announced that Quebec City will be home to its new production complex. The $245 million project will create 200 new high-skilled jobs by 2019, adding to the team of 180 employees already working at Medicago's Quebec City office and laboratories. The project is expected to generate more than $461 million in direct and indirect economic benefits over the next five years. Medicago chosed Quebec City because of its qualified employees and the access to an experienced workforce, world-class research infrastructure, a dynamic business culture and support from the federal, provincial and municipal governments. Medicago's new complex will be built in Quebec City'sEspace d'innovation D'Estimauville (Estimauville innovation park) and completed by 2019. It will regroup Medicago's head office, research and development activities, and commercial production plant. Medicago's new 44,000 m2 facility will be located on a 90,000 m2 site. It will have the capacity to deliver up to 40 to 50 million doses of quadrivalent seasonal flu vaccines. In addition, work towards developing new products will take place over the upcoming years. Medicago's innovative technology uses plants like miniature factories that can quickly produce large quantities of vaccines or treatments. This technology demonstrated its potential for responding to global pandemics when it produced candidate vaccines for H1N1 in 2009 and H7N9 in 2013 in just 19 days, compared to the several months required to produce vaccines using eggs.

Similar Private Companies By Industry

Company Name Region
2007262 Ontario, Inc. Americas
2056273 Ontario, Inc. Americas
AB BioPharma Inc. Americas
AbCelex Technologies Inc. Americas
AbCellera Biologics Inc. Americas

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Medicago Inc., please visit www.medicago.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.